Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents

被引：0
|
作者：
Hideaki Miyake
Ryo Sato
Kyohei Watanabe
Yuto Matsushita
Hiromitsu Watanabe
Daisuke Motoyama
Toshiki Ito
Takayuki Sugiyama
Atsushi Otsuka
机构：
[1] Hamamatsu University School of Medicine,Department of Urology
来源：
International Journal of Clinical Oncology | 2021年 / 26卷
关键词：
Metastatic castration-resistant prostate cancer; Cabazitaxel; Third-line treatment;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1745 / 1751
页数：6
相关论文
共 50 条
  • [1] Prognostic significance of third-line treatment for patients with metastatic castration-resistant prostate cancer: comparative assessments between cabazitaxel and other agents
    Miyake, Hideaki
    Sato, Ryo
    Watanabe, Kyohei
    Matsushita, Yuto
    Watanabe, Hiromitsu
    Motoyama, Daisuke
    Ito, Toshiki
    Sugiyama, Takayuki
    Otsuka, Atsushi
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (09) : 1745 - 1751
  • [2] Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer
    Kongsted, Per
    Svane, Inge M.
    Lindberg, Henriette
    Bisbjerg, Rasmus
    Daugaard, Gedske
    Sengelov, Lisa
    ANTI-CANCER DRUGS, 2016, 27 (07) : 695 - 701
  • [3] Cabazitaxel: A New Treatment for Metastatic Castration-Resistant Prostate Cancer
    Schwartz, Joanna R.
    Bottiglieri, Salvatore M.
    AMERICAN JOURNAL OF LIFESTYLE MEDICINE, 2013, 7 (01) : 66 - 72
  • [4] The role of cabazitaxel in the treatment of metastatic castration-resistant prostate cancer
    Tsao, Che-Kai
    Cutting, Elena
    Martin, Jacob
    Oh, William K.
    THERAPEUTIC ADVANCES IN UROLOGY, 2014, 6 (03) : 97 - 104
  • [5] Cabazitaxel in metastatic castration-resistant prostate cancer
    Yap, Timothy A.
    Pezaro, Carmel J.
    de Bono, Johann S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (09) : 1129 - 1136
  • [6] Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
    Paller, Channing J.
    Antonarakis, Emmanuel S.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2011, 5 : 117 - 124
  • [7] Metastatic castration-resistant prostate cancer: changing landscape with cabazitaxel
    Fernandez, Ovidio
    Afonso, Javier
    Vazquez, Sergio
    Campos, Begona
    Lazaro, Matin
    Leon, Luis
    Anton Aparicio, Luis M.
    ANTI-CANCER DRUGS, 2014, 25 (03) : 237 - 243
  • [8] Cabazitaxel schedules in metastatic castration-resistant prostate cancer: a review
    Pobel, Cedric
    Auclin, Edouard
    Procureur, Adrien
    Clement-Zhao, Alice
    Simonaggio, Audrey
    Delanoy, Nicolas
    Vano, Yann-Alexandre
    Thibault, Constance
    Oudard, Stephane
    FUTURE ONCOLOGY, 2021, 17 (01) : 91 - 102
  • [9] Cabazitaxel for the treatment of castration-resistant prostate cancer
    Agarwal, Neeraj
    Sonpavde, Guru
    Sartor, Oliver
    FUTURE ONCOLOGY, 2011, 7 (01) : 15 - 24
  • [10] Prognostic factors in men with metastatic castration-resistant prostate cancer treated with cabazitaxel
    Belderbos, Bodine P. S.
    de Wit, Ronald
    Oomen-de Hoop, Esther
    Nieuweboer, Annemieke
    Hamberg, Paul
    van Alphen, Robbert J.
    Bergman, Andre
    van der Meer, Nelly
    Bins, Sander
    Mathijssen, Ron H. J.
    van Soest, Robert J.
    ONCOTARGET, 2017, 8 (63) : 106468 - 106474
12345